Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Vinblastine, Cyclophosphamide, and Dacarbazine in Metastatic Melanoma
NCT01542255Phase 2Terminated
- Sponsor
- Dartmouth Health
- Start
- Jun 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinblastine, cyclophosphamide and dacarbazine in melanoma, sponsored by Dartmouth Health. Primary endpoint: Progression Free Survival at 100 months. Started Jun 2010; status: terminated.
02
Drugs
vinblastinecyclophosphamidedacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01542255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01542255.